A Phase I, Randomized, Double-blind, Single-dose, Partial Replicate, 3-way Cross-over Study to Assess the Total Systemic Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA in Healthy Adult Participants
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs Budesonide (Primary) ; Formoterol; Glycopyrrolate
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 13 Dec 2024 New trial record